<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>events &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/events/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 17 Oct 2026 18:41:27 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>events &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Lymphopenia emerges as earliest and most frequent blood toxicity in cervical cancer chemoradiation study</title>
		<link>https://bioengineer.org/lymphopenia-emerges-as-earliest-and-most-frequent-blood-toxicity-in-cervical-cancer-chemoradiation-study/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sat, 17 Oct 2026 18:41:27 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Adjuvant]]></category>
		<category><![CDATA[adverse]]></category>
		<category><![CDATA[associated]]></category>
		<category><![CDATA[cervical]]></category>
		<category><![CDATA[chemoradiotherapy]]></category>
		<category><![CDATA[concurrent]]></category>
		<category><![CDATA[events]]></category>
		<category><![CDATA[factors]]></category>
		<category><![CDATA[hematological]]></category>
		<category><![CDATA[influencing]]></category>
		<category><![CDATA[postoperative]]></category>
		<category><![CDATA[spectrum]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=431897</guid>

					<description><![CDATA[When a patient with cervical cancer finishes radical surgery and then faces weeks of postoperative adjuvant concurrent chemoradiotherapy, the treatment that helps destroy residual cancer cells can also quietly undermine the blood system that keeps the body defended and oxygenated.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">431897</post-id>	</item>
		<item>
		<title>FDA Database Study Flags Safety Signals for Widely Used HIV Drug Combination</title>
		<link>https://bioengineer.org/fda-database-study-flags-safety-signals-for-widely-used-hiv-drug-combination/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sat, 17 Oct 2026 18:17:41 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[adverse]]></category>
		<category><![CDATA[alafenamide]]></category>
		<category><![CDATA[bictegravir]]></category>
		<category><![CDATA[emtricitabine]]></category>
		<category><![CDATA[Event]]></category>
		<category><![CDATA[events]]></category>
		<category><![CDATA[Pharmacovigilance]]></category>
		<category><![CDATA[real-world]]></category>
		<category><![CDATA[reporting]]></category>
		<category><![CDATA[scientific research]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[tenofovir]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=431451</guid>

					<description><![CDATA[One of the most widely prescribed HIV treatments in the world is now the subject of a large-scale safety review, and the findings are prompting both reassurance and caution. A team of researchers from Beijing Ditan Hospital, Capital Medical University,]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">431451</post-id>	</item>
	</channel>
</rss>
